[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ablation-techniques\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ablation-techniques":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,42,68,96,118,163],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100641258","the-impact-of-anaesthesia-on-inflammation-and-netosis-in-hepatocellular-carcinoma-resection-100641258",false,"NCT07657897","The Impact of Anaesthesia on Inflammation and NETosis in Hepatocellular Carcinoma Resection","Inclusion Criteria:\n\n* patients with a hepatocellular carcinoma suitable for RFA\n* tumor measuring up to 3 cm in diameter\n* ASA I, II, or III\n\nExclusion Criteria:\n\n* candidates for surgery\n* chronic immunosuppressive medication\n* contraindications to any of the study medications\n* patients with psychiatric disorders\n* autoimmune disorders\n* corticosteroid-dependent bronchial asthma\n* congenital or acquired coagulation disorders\n* HIV-positive patients\n* pregnant women\n* antiarrhythmic therapy","ALL","18 Years","80 Years",{"count":19,"type":20},100,"ESTIMATED","INTERVENTIONAL",[23],"NA","According to recent literature, liver disease causes approximately 2 million deaths annually; 1 million are attributed to the complications of cirrhosis, while the remaining deaths are caused by hepatocellular carcinoma (HCC). The latter currently ranks 16th among the leading causes of death worldwide.\n\nCurrent research focuses on investigating novel therapeutic modalities, optimizing surgical and anesthetic practices, and identifying biological biomarkers to predict disease progression and severity. In this study, we address radiofrequency ablation (RFA) with the goal of improving periprocedural prognosis, recurrence rates, and overall survival. Specifically, we will quantify the expression of NETosis, a relatively novel biomarker with potential therapeutic and prognostic value in HCC progression. NETosis is a regulated form of cell death through which granulocytes release decondensed chromatin and various proteases into the extracellular space, forming a web-like meshwork known as neutrophil extracellular traps (NETs). These structures are actively involved in hepatic tumorigenesis by promoting tumor growth and metastasis.\n\nRecent clinical data reveal that NETs play a key role in:\n\nLocal tumor progression\n\nThe incidence of hepatic metastasis\n\nDirect modulation of the immune response\n\nHepatic ischemia-reperfusion injury\n\nSeveral recent studies demonstrate that the in vivo blockade of NETosis reduces tumor recurrence, mitigates the pro-inflammatory state, and serves as a valuable prognostic indicator in advanced liver disease \\[2,3,4\\]. To suppress NETosis expression and ultimately lower recurrence rates, our protocol evaluates the intraprocedural administration of 1% lidocaine followed by a continuous postoperative intravenous lidocaine infusion.",[26,27,28],"Hepato Cellular Carcinoma (HCC)","Sedation and Analgesia","Ablation Techniques","RECRUITING","2026-06-13",{"date":32,"type":33},"2026-06-18","ACTUAL",{"date":35,"type":33},"2024-11-12",{"date":37,"type":20},"2026-11-12",{"name":39,"class":40},"Iuliu Hatieganu University of Medicine and Pharmacy","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":49,"targetDuration":51,"studyType":52,"phases":4,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":41},"100640536","eus-guided-ablation-rfa-and-mwa-for-pancreatic-and-other-gastrointestinal-lesions-registry-100640536","NCT07625189","EUS-Guided Ablation (RFA and MWA) for Pancreatic and Other Gastrointestinal Lesions Registry","Prospective Observational Registry of EUS-Guided Ablation (RFA and MWA) for Pancreatic and Other Gastrointestinal Lesions","Inclusion Criteria:\n\n* Adults ≥ 18 years of age.\n* Diagnosis of a pancreatic premalignant lesion or malignancy, and other gastrointestinal or hepatobiliary lesion for which EUS-guided ablation is planned as part of standard clinical care.\n* At least one clinically identified target lesion for which RFA or MWA is performed.\n\nExclusion Criteria:\n\n* In the judgment of the treating clinician, inclusion in the registry would not be appropriate\n* The individual is expected to be unable to complete routine clinical follow-up.",{"count":50,"type":20},50,"1 Year","OBSERVATIONAL","This is a single-center, investigator-initiated, prospective observational registry that will collect longitudinal clinical data on adult patients (≥18 years) undergoing endoscopic ultrasound (EUS)-guided radiofrequency ablation (RFA) or microwave ablation (MWA) for pancreatic and other gastrointestinal\u002Fhepatobiliary lesions as part of routine clinical care. The registry will not alter standard-of-care management. Data will be abstracted from the medical record and routine clinical systems. Primary outcomes include change in target lesion size on clinically obtained imaging and overall survival following ablation. Secondary outcomes include changes in tumor biomarkers, adverse events, non-target lesion changes, and patient-reported symptoms.",[55,56,57,58,28],"RFA","Microwave Ablation","Pancreatic Lesion","Gastrointestinal Lesions","2026-05-30",{"date":61,"type":33},"2026-06-04",{"date":63,"type":33},"2026-03-10",{"date":65,"type":20},"2028-03",{"name":67,"class":40},"West Virginia University",{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":75,"enrollmentInfo":76,"targetDuration":4,"studyType":21,"phases":78,"briefSummary":79,"conditions":80,"keywords":84,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":41},"100603840","electroporation-vs-radiofrequency-ablation-guided-by-3d-imaging-in-repeat-procedures-for-atrial-fibrillation-100603840","NCT07141745","Electroporation vs. Radiofrequency Ablation Guided by 3D Imaging in Repeat Procedures for Atrial Fibrillation","ERA-rePVI","Inclusion Criteria:\n\nDocumented recurrence of AF or atypical atrial flutter after prior PVI Eligibility for re-PVI\n\nExclusion Criteria:\n\nLeft ventricular ejection fraction \\\u003C 30% Left atrial volume index (LAVI) \\> 72 mL\u002Fm² Untreated hyperthyroidism Hypertrophic cardiomyopathy Severe valvular heart disease","85 Years",{"count":77,"type":20},250,[23],"This is a prospective, randomized clinical trial evaluating the efficacy and safety of two techniques for repeat catheter ablation in patients with recurrent atrial fibrillation (AF): thermal energy ablation (radiofrequency) and non-thermal electroporation (pulsed field ablation), both guided by 3D imaging systems.\n\nPatients undergoing repeat AF ablation will be randomly assigned to receive either thermal or electroporation ablation, performed according to standard hospital protocols. No additional invasive procedures are required. Following the ablation, participants will attend follow-up visits at 3, 6, and 12 months, including medical history review, physical examination, 12-lead ECG, and 24-hour Holter monitoring. Unscheduled ECG assessments will also be available if arrhythmia symptoms occur.\n\nAll study-related procedures are non-invasive and align with routine post-ablation care. Risks are limited to those typically associated with standard AF ablation procedures.\n\nThe main benefit of participation is close, structured follow-up by experienced electrophysiologists, allowing for early detection of arrhythmia recurrence and timely medical intervention when necessary.\n\nParticipant confidentiality and data protection will be ensured in accordance with GDPR regulations.",[81,28,82,83],"Atrial Fibrillation (AF)","Radiofrequency Catheter Ablation","Pulsed Field Ablation",[85,83,82,86],"Atrial fibrillation re-ablation","Atrial firbillation reccurence","2025-08-26",{"date":89,"type":33},"2025-08-27",{"date":91,"type":20},"2025-08-30",{"date":93,"type":20},"2028-10-01",{"name":95,"class":40},"Wroclaw Medical University",{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":100,"acronym":101,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":103,"targetDuration":105,"studyType":52,"phases":4,"briefSummary":106,"conditions":107,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":41},"100601334","registry-of-atrial-arrhythmia-ablation-procedures-using-pulsed-field-ablation-in-poland-100601334","NCT07109141","Registry of Atrial Arrhythmia Ablation Procedures Using Pulsed Field Ablation in Poland","PFA Registry","Inclusion Criteria:\n\n* Informed consent obtained from the participant\n* Subject is undergoing ablation of an atrial arrhythmia using the PFA\n\nExclusion Criteria:\n\n\\-",{"count":104,"type":20},500,"12 Months","The aim of the described project is to establish a multicenter, nationwide registry of atrial arrhythmia ablation procedures using the Pulsed Field Ablation (PFA) method. These procedures have only recently begun to be performed in several centers across Poland. With proper coordination of the registry, this will enable the consolidation of clinical data and the expansion of knowledge regarding the efficacy and safety of these procedures.",[81,108,109,28,83],"Atrial Flutter","Atrial Tachycardia","2025-07-31",{"date":112,"type":33},"2025-08-07",{"date":114,"type":33},"2024-08-01",{"date":116,"type":20},"2030-07-01",{"name":95,"class":40},{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":124,"eligibilityCriteria":125,"healthyVolunteers":11,"sex":15,"minAge":126,"maxAge":127,"enrollmentInfo":128,"targetDuration":4,"studyType":21,"phases":130,"briefSummary":131,"conditions":132,"keywords":138,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":162},"100572518","maintain-mucosal-ablation-therapy-after-incretins-100572518","NCT06734312","MAINTAIN (Mucosal AblatIoN Therapy After INcretins)","Gastric Fundal Mucosal Ablation for Weight Management in Patients Stopping Glucagon-like Peptide-1 Receptor Agonists","MAINTAIN","Inclusion Criteria:\n\n1. Subjects aged 21-65\n2. Body mass Index (BMI) ≥30 kilograms per square meter (kg\u002Fm²), or ≤45 kg\u002Fm²\n3. Observed ≥ 10% TBWL with semaglutide or tirzepatide use for primary obesity therapy\n4. Subject did not experience \\>50% weight recurrence since discontinuation of semaglutide or tirzepatide\n5. Maintained a stable dose of semaglutide or tirzepatide for a minimum of 12 weeks\n6. Have recently discontinued or are planning to discontinue semaglutide or tirzepatide (≤ 24 weeks from last dose to time of study procedure)\n7. No previous medical history of diabetes mellitus\n8. Willing and able to participate in the study procedures\n9. Understand and voluntarily sign the informed consent\n\nExclusion Criteria:\n\n1. Known diagnosis of type I or type II diabetes or a Hemoglobin A1c \\> 6.5% at time of screening\n2. Use of GLP-1 or GLP-1\u002FGIP medication for the treatment of diabetes, rather than obesity.\n3. Use of anticoagulation, antithrombotic agents, and\u002For NSAIDs that cannot be discontinued for a minimum of 12 weeks\n4. Known bleeding diathesis that cannot be corrected through medical means.\n5. History of decompensated end-organ disease\n6. Unwillingness to abstain from the use of incretin mimetics during the study duration.\n7. Unwillingness to abstain from the use of tobacco during the study duration\n8. Patients on any medications or supplements including those that may influence cholecystokinin (CCK), glucose, growth hormone, insulin and\u002For somatostatin levels\n9. History of any stomach manipulation (including repair of hiatal hernia or fundoplication) deemed unsafe by PI for GFMA\n10. Active disordered eating\n11. Patients who do not give their consent to the enrollment in the study or are incompetent, unconscious or unable to express their consent for any reason\n12. Known diagnosis of gastroparesis or functional dyspepsia\n13. Patients who are pregnant, who plan to become pregnant during study duration, or patients of child-bearing potential who refuse effective birth control methods (as approved by PI)\n14. Active H. pylori infection or history of H pylori without treatment and confirmation of eradication\n15. Active gastric ulceration.\n16. Use of concomitant medications known to induce weight loss (including but not limited to liraglutide, phentermine, phentermine\u002Ftopiramate, bupropion\u002Fnaltrexone, metformin)","21 Years","65 Years",{"count":129,"type":20},20,[23],"The purpose of this study is to assess the effect of gastric fundal mucosal ablation (GFMA) on weight trajectory following discontinuation of once-weekly semaglutide or tirzepatide in adults with obesity. In this study, GFMA will be performed on patients who have experienced \\> 10% weight loss with GLP-1 therapy and who plan to discontinue use of GLP-1 medications for the duration of the study.",[133,134,135,136,137,28],"Obesity and Obesity-related Medical Conditions","Obesity and Overweight","Obesity Prevention","Obesity Recidivism","GLP-1",[139,140,141,142,143,144,145,146,147,148,149,150,151,152],"obesity","obesity and overweight","endoscopic bariatric therapy","ablation","gastric mucosal ablation","GMA","GFMA","glp-1","weight loss medications","weight loss","semaglutide","tirzepatide","hunger","appetite","2025-03-18",{"date":155,"type":33},"2025-03-21",{"date":157,"type":33},"2025-01-01",{"date":159,"type":20},"2026-06",{"name":161,"class":40},"Dr. Christopher McGowan",2,{"id":164,"slug":165,"hasResults":11,"nctId":166,"briefTitle":167,"officialTitle":168,"acronym":169,"eligibilityCriteria":170,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":171,"targetDuration":4,"studyType":21,"phases":173,"briefSummary":174,"conditions":175,"keywords":181,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":190,"startDateStruct":192,"completionDateStruct":193,"leadSponsor":195,"locationsCount":197},"100543508","longitudinal-study-of-local-ablative-therapy-in-oligometastatic-disease-100543508","NCT06356779","Longitudinal Study of Local Ablative Therapy in Oligometastatic Disease","A National Longitudinal Study of Metastases-directed Local Ablative Therapy for Patients With Oligometastatic Disease - a Combined Interventional and Observational Trial","OLIGO-DK","Inclusion Criteria:\n\n* Histology or cytology proven non-haematological cancer\n* Stage IV disease\n* ECOG performance status ≤ 2\n* Life expectancy \\> 6 months\n* A baseline scan within 42 days of inclusion (PET-CT or CT or MRI scan) is required, preferably within 28 days for optimal prospective evaluation\n* Primary tumor must be controlled, defined by the radiographical response of the primary tumor by systemic or local treatment. If progressing, it is planned to be treated with local ablative therapy (LAT)\n* Oligometastatic disease according to the ESTRO-EORTC classification, both de-novo and induced, including oligoprogression\n* A maximum of five oligometastases or oligopersistent\u002Foligoprogressive lesions. More than five metastases are allowed in the following cases, 1) location in a defined anatomical entity or 2) location in immediate proximity and as such, cannot be treated separately\n* All oligometastatic lesions must be planned for definitive LAT. If all visible\u002Fprogressive\u002Fpersistent disease is not treated, the patient cannot be included\n* Local ablative therapy must be deemed clinically relevant for the individual patient by the treating team of physicians, or a multidisciplinary team and discussion must be documented in the patient chart\n* Ability to understand and the willingness to sign a written informed consent document\n\nExclusion Criteria:\n\n* Pregnancy\n* Diffuse cancer disease, which cannot be locally ablated, i.e., leptomeningeal carcinomatosis, malignant pleural effusions, lymphangitic carcinomatosis, or peritoneal carcinomatosis\n* If LAT is deemed unsafe by the MDT (e.g., tumor perforation of hollow organs)\n\nIn addition, the patients receiving SBRT to oligometastatic sites should comply with the following criteria.\n\n* The size of the target is limited by the ability to safely deliver locally ablative doses to the metastatic lesions. Generally, an upper limit of 5 cm is recommended\n* If the patient has received previous radiotherapy, the combined dose at the radiation site must not exceed the dose constraints according to Appendix 2 - Radiotherapy Recommendations",{"count":172,"type":20},1200,[23],"This prospective national multicenter observational and interventional study aims to assess the longitudinal disease trajectory of patients with oligometastatic disease (OMD) who receive local metastasis-directed therapy. Patients with any category of OMD from any non-hematological cancer are eligible for inclusion. Local ablative therapy (LAT) includes surgical metastasectomy, radiotherapy, thermal ablation, and electroporations.\n\nThe primary objective is to assess the time to failure of LAT strategy in patients with OMD from any primary cancer treated with all LAT modalities.",[176,177,28,178,179,180],"Oligometastatic Disease","Metastases","Radiotherapy","Stereotactic Radiation","Surgery",[182,183,184,185,186,187,188],"oligometastatic disease","metastases-directed therapy","metastasectomy","thermal ablation","stereotactic ablative radiotherapy","stereotactic radiosurgery","endpoints","2024-04-15",{"date":191,"type":33},"2024-04-16",{"date":189,"type":33},{"date":194,"type":20},"2035-12-31",{"name":196,"class":40},"Gitte Fredberg Persson MD PhD",11]